Novo Nordisk wants to make another major capital investment in production capacity for its diabetes and obesity therapies. The Danish drugmaker announced to spend more...
Last week, Lonza and Vertex Pharmaceuticals broke ground on a new US facility in Portsmouth, New Hampshire, to manufacture cell therapies for diabetes.
Danish drugmaker Novo Nordisk has agreed to acquire Montreal, Canada-based Inversago Pharma. The transaction is worth up to $1.075 billion in cash if certain development...
US-based Vertex Pharmaceuticals has agreed to pay $320 million in cash to acquire ViaCyte, a compatriot private cellular therapy company specializing in a treatment for...
13.02.2018
- Danish drugmaker Novo Nordisk has been granted marketing approval by the European Commission for its Ozempic (semaglutide) diabetes treatment. The once-weekly drug, a glucagon-like...
22.01.2018
- Chinese companies are said to be taking great interest in the diabetes care business Johnson & Johnson may put up for sale. The news agency Reuters, citing “five people with direct...
27.04.2017
- Bioelectronic technologies for modulating the signaling capabilities of the nervous system could pose challenges for producers of medicinal materials and chemicals – but also for...
05.04.2017
- US drugmaker Eli Lilly has announced plans to invest $850 million in its US operations during 2017, including an $85 million expansion of its Trulicity (dulaglutide) device...
